• 1
    Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control Sep 1997; 8: 75563.
  • 2
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J, Parkin DM. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer 2000; 86: 42935.
  • 3
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998; 75: 53645.
  • 4
    Visioli CB, Zappa M, Ciatto S, Iossa A, Crocetti E. Increasing trends of cervical adenocarcinoma incidence in Central Italy despite Extensive Screening Program, 1985–2000. Cancer Detect Prev 2004; 28: 4614.
  • 5
    Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev Sep 2005; 14: 21919.
  • 6
    Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer Sep 1999; 81: 15966.
  • 7
    ICESCC. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2006; 120: 88591.
  • 8
    Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 6373.
  • 9
    Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 30315.
  • 10
    Gustafsson L, Sparen P, Gustafsson M, Wilander E, Bergstrom R, Adami HO. Efficiency of organized and opportunistic cytological screening for cancer in situ of the cervix. Br J Cancer 1995; 72: 498505.
  • 11
    Sparen P. Cervical screening in Sweden in 2006. Report from the National Cervical Screening Register. Stockholm: Karolinska Institutet, 2007. Available at:
  • 12
    Cancerregistret. Cancer incidence in Sweden 2007. Official statistics of Sweden. Stockholm: Swedish Cancer Registry, National Board of Health and Welfare, 2008.
  • 13
    Ylitalo N, Josefsson A, Melbye M, Sorensen P, Frisch M, Andersen PK, Sparen P, Gustafsson M, Magnusson P, Ponten J, Gyllensten U, Adami HO. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000; 60: 602732.
  • 14
    Chua KL, Hjerpe A. Polymerase chain reaction analysis of human papillomavirus in archival cervical cytologic smears. Anal Quant Cytol Histol 1995; 17: 2219.
  • 15
    de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 1995; 76 ( Part 4): 105762.
  • 16
    Soderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 2009; 47: 5416.
  • 17
    Kuritz SJ, Landis JR. Attributable risk estimation from matched case-control data. Biometrics 1988; 44: 35567.
  • 18
    Development Core Team R. A language and environment for statistical computing. R Foundation for Statistical Computing, 2008. Available at: http://www.R-project. org.
  • 19
    Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, Richart RM, Isacson C. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000; 157: 105562.
  • 20
    Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001; 37: 24650.
  • 21
    Zielinski GD, Snijders PJ, Rozendaal L, Daalmeijer NF, Risse EK, Voorhorst FJ, Jiwa NM, van der Linden HC, de Schipper FA, Runsink AP, Meijer CJ. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003; 201: 53543.
  • 22
    Tawfik El-Mansi M, Cuschieri KS, Morris RG, Williams AR. Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer 2006; 16: 102531.
  • 23
    Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in the Netherlands. Br J Cancer 2006; 94: 1715.
  • 24
    Chew GK, Cruickshank ME, Rooney PH, Miller ID, Parkin DE, Murray GI. Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer 2005; 93: 13014.
  • 25
    Rohan T. The epidemiology of adenocarcinoma of the cervix. In: RohanT, ShahK, eds. Cervical cancer: from etiology to prevention. Dordrecht: Kluwer Academic Publishers, 2004. 21734.
  • 26
    Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009; 125: 5259.
  • 27
    Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100: 6229.